Exploration of genetic characterization in hyperprogressive disease after immunotherapy retreatment in a patient with LCNEC: A case report
Immune checkpoint inhibitors (ICIs) have emerged as a promising therapeutic option for large cell neuroendocrine carcinoma (LCNEC). However, various studies have suggested a potential risk of hyperprogressive disease (HPD) in patients receiving ICI, which might be associated with gene alterations. H...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2024.2313281 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850124108424019968 |
|---|---|
| author | Yao Zhang Jiayao Yang Tianyu Shao Jialu Chen Qijin Shu Liumei Shou |
| author_facet | Yao Zhang Jiayao Yang Tianyu Shao Jialu Chen Qijin Shu Liumei Shou |
| author_sort | Yao Zhang |
| collection | DOAJ |
| description | Immune checkpoint inhibitors (ICIs) have emerged as a promising therapeutic option for large cell neuroendocrine carcinoma (LCNEC). However, various studies have suggested a potential risk of hyperprogressive disease (HPD) in patients receiving ICI, which might be associated with gene alterations. Here, this is the first report on an unknown primary LCNEC patient who had achieved a long-term response from ICI treatment (atezolizumab), but developed HPD after tumor progression due to receiving another ICI agent (serplulimab). The mutation region of FAT4, SMARCA4, CYLD, CTNNB1, and KIT was altered prior to serplulimab treatment compared to before atezolizumab treatment. This case suggested a potential association between these mutated genes and HPD. Patients with the aforementioned genes should caution when selecting ICI treatment. These findings required further confirmation in a larger study cohort. |
| format | Article |
| id | doaj-art-4bdbddadbc0142e580911cf85e32913c |
| institution | OA Journals |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-4bdbddadbc0142e580911cf85e32913c2025-08-20T02:34:25ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2024-12-0120110.1080/21645515.2024.2313281Exploration of genetic characterization in hyperprogressive disease after immunotherapy retreatment in a patient with LCNEC: A case reportYao Zhang0Jiayao Yang1Tianyu Shao2Jialu Chen3Qijin Shu4Liumei Shou5The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, ChinaThe First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, ChinaDepartment of Oncology, Guang’ Anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, ChinaDepartment of Oncology, Hangzhou Third People’s Hospital, Hangzhou, ChinaDepartment of Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, ChinaDepartment of Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, ChinaImmune checkpoint inhibitors (ICIs) have emerged as a promising therapeutic option for large cell neuroendocrine carcinoma (LCNEC). However, various studies have suggested a potential risk of hyperprogressive disease (HPD) in patients receiving ICI, which might be associated with gene alterations. Here, this is the first report on an unknown primary LCNEC patient who had achieved a long-term response from ICI treatment (atezolizumab), but developed HPD after tumor progression due to receiving another ICI agent (serplulimab). The mutation region of FAT4, SMARCA4, CYLD, CTNNB1, and KIT was altered prior to serplulimab treatment compared to before atezolizumab treatment. This case suggested a potential association between these mutated genes and HPD. Patients with the aforementioned genes should caution when selecting ICI treatment. These findings required further confirmation in a larger study cohort.https://www.tandfonline.com/doi/10.1080/21645515.2024.2313281Large cell neuroendocrine carcinoma (LCNEC)immune checkpoint inhibitors (ICIs)retreatment with immunotherapyhyperprogressive disease (HPD)genetic characterization |
| spellingShingle | Yao Zhang Jiayao Yang Tianyu Shao Jialu Chen Qijin Shu Liumei Shou Exploration of genetic characterization in hyperprogressive disease after immunotherapy retreatment in a patient with LCNEC: A case report Human Vaccines & Immunotherapeutics Large cell neuroendocrine carcinoma (LCNEC) immune checkpoint inhibitors (ICIs) retreatment with immunotherapy hyperprogressive disease (HPD) genetic characterization |
| title | Exploration of genetic characterization in hyperprogressive disease after immunotherapy retreatment in a patient with LCNEC: A case report |
| title_full | Exploration of genetic characterization in hyperprogressive disease after immunotherapy retreatment in a patient with LCNEC: A case report |
| title_fullStr | Exploration of genetic characterization in hyperprogressive disease after immunotherapy retreatment in a patient with LCNEC: A case report |
| title_full_unstemmed | Exploration of genetic characterization in hyperprogressive disease after immunotherapy retreatment in a patient with LCNEC: A case report |
| title_short | Exploration of genetic characterization in hyperprogressive disease after immunotherapy retreatment in a patient with LCNEC: A case report |
| title_sort | exploration of genetic characterization in hyperprogressive disease after immunotherapy retreatment in a patient with lcnec a case report |
| topic | Large cell neuroendocrine carcinoma (LCNEC) immune checkpoint inhibitors (ICIs) retreatment with immunotherapy hyperprogressive disease (HPD) genetic characterization |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2024.2313281 |
| work_keys_str_mv | AT yaozhang explorationofgeneticcharacterizationinhyperprogressivediseaseafterimmunotherapyretreatmentinapatientwithlcnecacasereport AT jiayaoyang explorationofgeneticcharacterizationinhyperprogressivediseaseafterimmunotherapyretreatmentinapatientwithlcnecacasereport AT tianyushao explorationofgeneticcharacterizationinhyperprogressivediseaseafterimmunotherapyretreatmentinapatientwithlcnecacasereport AT jialuchen explorationofgeneticcharacterizationinhyperprogressivediseaseafterimmunotherapyretreatmentinapatientwithlcnecacasereport AT qijinshu explorationofgeneticcharacterizationinhyperprogressivediseaseafterimmunotherapyretreatmentinapatientwithlcnecacasereport AT liumeishou explorationofgeneticcharacterizationinhyperprogressivediseaseafterimmunotherapyretreatmentinapatientwithlcnecacasereport |